Ribupatide (HRS9531) is a GLP-1/GIP dual receptor agonist developed by China's Hengrui Pharma and licensed to Kailera Therapeutics outside Greater China. It shares its dual incretin mechanism with Lilly's tirzepatide and is being developed in two forms: a once-weekly injection, which is the lead program, and an oral tablet.
The injection is in Phase 3. On September 30, 2026, Kailera said it had finished enrolling about 4,900 adults in its three-trial KaiNETIC program, which runs 76 weeks and includes KaiNETIC-3, a head-to-head comparison with semaglutide 2.4 mg in about 1,200 people with a BMI of 35 or higher. Topline results are expected in mid-2028.
The oral version is earlier. A 26-week Phase 2 trial of the tablet in 166 Chinese adults with obesity, reported in February 2026, showed weight loss of up to about 12% versus about 2% on placebo, with vomiting in 11.4% and 7.5% of the top two dose groups. Kailera planned a global Phase 2 of the oral form in 2026.
Stories here cover ribupatide trial readouts and the Kailera-Hengrui partnership. See #kailera, #hengrui, and #oral-glp-1.
A Phase 2 trial of ribupatide, the weekly GLP-1/GIP dual agonist injection that Hengrui licensed to Kailera Therapeutics outside Greater China, enrolled 158 Chinese women aged 18 to 40 with obesity or overweight and polyendocrine metabolic ovarian syndrome (PMOS). After 32 weeks, weight fell 10% on 1 mg, 15.1% on 2 mg, and 20.2% on 4 mg versus 2.6% on placebo, according to an EASD abstract reported by BioSpace on Friday, October 2, 2026. All three ribupatide groups had more frequent menstrual cycles, while cycles became less frequent on placebo, and there were no serious adverse events or adverse events that led to stopping the study.
Kailera Therapeutics said on Wednesday, September 30, 2026 that it has finished enrolling about 4,900 adults in the three-trial KaiNETIC Phase 3 program for ribupatide, a weekly GLP-1/GIP dual agonist licensed from Hengrui, including KaiNETIC-3, which compares ribupatide with semaglutide 2.4 mg in about 1,200 people with a BMI of 35 or higher. Each trial runs 76 weeks with titration up to 10 mg, and topline results are expected in mid-2028. At EASD on October 1, Kailera reported a 51-person Phase 1 study in which ribupatide exposure after injection in the upper arm or thigh was similar to abdominal injection, and early Phase 1 data for the triple agonist HRS-4729 showing 16.0% mean weight loss at week 12 on 12 mg in 10 participants.
Kailera Therapeutics (NASDAQ: KLRA) holds rights outside Greater China to several Hengrui Pharma obesity drugs. Ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP dual agonist, is in the three-trial global KaiNETIC Phase 3 program, which had enrolled more than 4,700 participants as of August 12, 2026, testing doses up to 10 mg over 76 weeks with data expected in 2028. KAI-7535 (HRS-7535) is a separate drug, a once-daily oral small-molecule GLP-1 receptor agonist, now in a roughly 320-person global Phase 2 trial in the U.S. and Australia with data expected in 2027; Kailera's GLP-1/GIP/glucagon triple agonist is a third drug, HRS-4729.
Chinese innovative drug developer Haisco Pharmaceutical Group (SHE: 002653) entered Wednesday August 26, 2026 an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners. Financial terms and specific asset details for the Haisco-Sentivera agreement have not been fully publicly disclosed in initial press coverage; additional detail is expected in the deal filing documents. The transaction extends the growing Chinese biotech pattern of ex-China commercialization partnerships that has substantially accelerated across 2025 and 2026. Recent comparable transactions include: Hengrui Pharma to Kailera Therapeutics for ribupatide (once-weekly injectable GLP-1/GIP dual agonist peptide, in Kailera's global Phase 3 KaiNETIC program); Hanmi Pharm to Genentech for HM17321 (urocortin-2 analog peptide for obesity via CRFR2 receptor, $190 million upfront + up to $2.3 billion in milestones + tiered royalties, announced August 24); Innovent Biologics' IBI3032 receiving FDA IND clearance August 5 and multiple additional Chinese CDE implied licenses August 18 for synchronized dual-region development; and Minwei Bio's MWN105 Phase Ib registration August 19-20 targeting semaglutide-intolerant populations. The pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches, and it also reflects US venture capital interest in accessing Chinese-originated clinical-stage assets at attractive valuations relative to comparable US biotech candidates.
Kailera Therapeutics (NASDAQ: KLRA) received sweeping positive analyst coverage following its August 12, 2026 Q2 2026 earnings report. Kailera confirmed an active Investigational New Drug (IND) application with the FDA for ribupatide oral (KAI-9531-T) and global Phase 3 obesity trials planned for H1 2027. Analyst response: according to 6 analysts, the average rating for KLRA stock is Strong Buy, with a 12-month average price target of $42.60 representing 82.83% upside from the $17.95-$19.50 trading range on August 13-14. Named ratings include TD Cowen at Buy with a $57 price target, Evercore ISI at Outperform, and William Blair at Outperform. The company holds cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028. Ribupatide mechanism: a once-weekly GLP-1/GIP dual agonist peptide (mechanistically similar to Eli Lilly's tirzepatide) with the ribupatide injection Phase 2 trial reaching 23.6% mean weight loss at 8 mg over 36 weeks, and the oral formulation reaching up to 12.1% weight loss with 38.6% of participants achieving at least 15% loss at Week 26 in Hengrui's Phase 2 trial. The Phase 2b high-dose injection trial in obesity is fully enrolled with data anticipated in mid-2027.
Kailera Therapeutics (NASDAQ: KLRA) reported August 12, 2026 Q2 2026 financial results and disclosed an active Investigational New Drug (IND) application with the US FDA for ribupatide oral (KAI-9531-T), a once-daily form of the GLP-1/GIP dual agonist peptide ribupatide for obesity, being co-developed with Hengrui Pharma. Global Phase 3 obesity trials are planned to initiate in H1 2027. Phase 2 data foundation: Hengrui's Phase 2 trial in adults with obesity documented up to 12.1% mean weight loss with no observed plateau at Week 26 and up to 38.6% of participants achieving at least 15% weight loss at the 25 mg and 50 mg once-daily oral doses. A ribupatide injection Phase 2b high-dose trial in obesity is fully enrolled with data anticipated in mid-2027. Ribupatide acts on the same two receptors as Eli Lilly's tirzepatide, and its weekly injectable form is already in Kailera's global Phase 3 KaiNETIC program. The oral formulation could compete with Lilly's orforglipron (oral small-molecule GLP-1 agonist, roughly 7.5-11.2% weight loss over 72 weeks) and Novo Nordisk's Wegovy pill (oral semaglutide 25 mg). Kailera holds US and ex-China commercial rights via a license from Hengrui.
Monday's data sharpened the oral GLP-1 competitive map. Lilly's Foundayo (orforglipron) leads with a Phase 3 head-to-head win over oral semaglutide and a Q2 FDA filing pending. Structure's aleniglipron sits closest, with 16.3% Phase 2b weight loss and Nature Medicine publication on Friday. AstraZeneca's elecoglipron just cleared Phase 2b. Chinese entrants Hengrui-Kailera (ribupatide, HRS-7535) added Phase 2 and 3 readouts. Novo's Wegovy pill remains the only currently-approved oral, but the next-wave field is now broad and head-to-head data are arriving fast.
The American Diabetes Association's 86th Scientific Sessions run June 5-8, with a Phase 3 retatrutide symposium June 6 (TRIUMPH-1 and TRANSCEND-T2D-1) and a Foundayo/orforglipron symposium June 8. Beyond Lilly and Novo, the oral-incretin race fills the program: Structure's aleniglipron, Hengrui and Kailera's oral GLP-1/GIP ribupatide (up to 12.1% in Phase 2), and Boehringer/Zealand's survodutide SYNCHRONIZE-1 in obesity. More than 12,000 attendees are expected.
Obesity biotech Kailera Therapeutics priced an upsized IPO of 39.06 million shares at $16, raising $625 million — the largest venture-backed biopharmaceutical IPO since Acelyrin in 2023. Lead candidate ribupatide (a GLP-1/GIP peptide dual agonist) drove 18% body weight loss at 48 weeks in a late-stage Chinese study; global Phase 3 readout expected in 2028.